Inventor · disambiguated record
Kevin J. Klopfer
Also filed as: KLOPFER KEVIN · KLOPFER KEVIN J · KLOPFER KEVIN JOSEPH
18 granted patents·6 pending applications·47 citations·filing 2003–2020
91Inventor score
Top patents by PatentIndex Score
24 records- 0196US9695146B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted Jul 4, 2017·17 cites·43 claims
- 0291US10376503B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2018·Granted Aug 13, 2019·2 cites·38 claims
- 0388US9974780B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2017·Granted May 22, 2018·2 cites·38 claims
- 0488US9403829B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2012·Granted Aug 2, 2016·13 cites·29 claims
- 0582US9968627B2Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted May 15, 2018·2 cites·21 claims
- 0679US9808450B2Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted Nov 7, 2017·1 cites·38 claims
- 0776US9085551B2Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2013·Granted Jul 21, 2015·1 cites·5 claims
- 0876US8207221B2Crystalline polymorphs of a CXC-chemokine receptor ligandHU MENGWEI·Filed 2008·Granted Jun 26, 2012·2 cites·5 claims
- 0973US11406629B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2020·Granted Aug 9, 2022·0 cites·27 claims
- 1072US7521452B2Preparation of pharmaceutical salts of piperazine compoundsSCHERING CORP·Filed 2006·Granted Apr 21, 2009·1 cites·9 claims
- 1171US10835522B2Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted Nov 17, 2020·0 cites·38 claims
- 1271US9604939B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2014·Granted Mar 28, 2017·1 cites·10 claims
- 1366US7192962B2Xanthine phosphodiesterase V inhibitor polymorphsSCHERING CORP·Filed 2003·Granted Mar 20, 2007·5 cites·26 claims
- 1464US10052323B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2018·Granted Aug 21, 2018·0 cites·7 claims
- 1559US9974786B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted May 22, 2018·0 cites·18 claims
- 1658US9795603B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Oct 24, 2017·0 cites·18 claims
- 1757US2018000808A1Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2017·Application pending·0 cites
- 1856US2009093496A1Preparation of pharmaceutical salts of piperazine compoundsWU WENXUE·Filed 2008·Application pending·0 cites
- 1953US12215094B2Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-olCELGENE CORP·Filed 2019·Granted Feb 4, 2025·0 cites·23 claims
- 2048US2005192345A1Crystalline polymorphs of a CXC-chemokine receptor ligandSCHERING CORP·Filed 2005·Application pending·0 cites
- 2146US2020392491A1Method of Preparing Oligonucleotide CompoundsNOGRA PHARMA LTD·Filed 2018·Application pending·0 cites
- 2245US2022017489A1Solid dispersions for treatment of cancerCELGENE CORP·Filed 2019·Application pending·0 cites
- 2342US9718824B2Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereofSIGNAL PHARM LLC·Filed 2015·Granted Aug 1, 2017·0 cites·53 claims
- 2440US2022017490A1Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereofCELGENE CORP·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →